Get the Stockscreener App
0.72
4.67%
0.0321
After Hours:
.72
Polyrizon Ltd stock is traded at $0.72, with a volume of 254.51K.
It is up +4.67% in the last 24 hours and down -15.29% over the past month.
Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. Its technology platforms are Capture & Contain and Trap & Target.
See More
Previous Close:
$0.6879
Open:
$0.663
24h Volume:
254.51K
Relative Volume:
0.10
Market Cap:
$4.31M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-9.89%
1M Performance:
-15.29%
6M Performance:
-99.86%
1Y Performance:
+0.00%
1-Day Range:
$0.663
$0.733
1-Week Range:
$0.663
$0.7899
52-Week Range:
$0.55
$1,200.00
Polyrizon Ltd Stock (PLRZ) Company Profile
Compare PLRZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLRZ
Polyrizon Ltd
|
0.72 | 4.31M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.27 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
522.27 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.00 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
568.06 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
266.80 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Polyrizon Ltd Stock (PLRZ) Latest News
Polyrizon Ltd Inc. (PLRZ) Price Performance: How to Use Technical Analysis to Make Trading Decisions - investchronicle.com
Polyrizon’s nasal drug delivery system shows promising results By Investing.com - Investing.com South Africa
Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics - MarketScreener
Polyrizon’s nasal drug delivery system shows promising results - Investing.com Australia
Polyrizon Announces Promising Preclinical Results for CNS Therapeutics - TipRanks
Revolutionary Nasal Drug Delivery System Could Transform Treatment of Opioid Overdose and Epilepsy - Stock Titan
Smart Digital Group And Polyrizon See Unusual Market Moves - Finimize
Polyrizon Ltd. Announces Reverse Share Split Effective May 27, 2025 - TipRanks
Polyrizon recives Nasdaq delisting notice - MSN
Polyrizon faces Nasdaq delisting over shareholder dilution By Investing.com - Investing.com India
Polyrizon Stock Price, Quotes and Forecasts | NASDAQ:PLRZ - Benzinga
Polyrizon faces Nasdaq delisting over shareholder dilution - Investing.com Australia
Polyrizon Receives Nasdaq Delisting Notice Amid Shareholder Concerns - TipRanks
Polyrizon Receives Nasdaq Delisting Notice - marketscreener.com
Polyrizon receives noncompliance letter from Nasdaq - TipRanks
Polyrizon Announces Receipt of Nasdaq Delisting Notice - The Manila Times
Polyrizon announces preclinical data on nasal protection platform - TipRanks
Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform - Bluefield Daily Telegraph
Revolutionary Nasal Drug Delivery Platform Achieves Perfect Coverage Score in Latest Tests - Stock Titan
Pennies on the Rise: HCTI, SWISF, ADHC, NCNA Gain Traction Amid LargeCap Uncertainty – More Stocks Inside - FinancialContent
Polyrizon Ltd. Increases Outstanding Shares Following Warrant Exercises - TipRanks
Polyrizon Ltd. Announces Increase in Outstanding Shares Following Warrant Exercises - TipRanks
Nasdaq Gains Over 100 Points; Sony Group Posts Upbeat Earnings - Benzinga
Nasdaq Rises Over 1%; Under Armour Posts Strong Q4 Sales - Benzinga
Polyrizon begins preclinical studies for seizure treatment - Investing.com Australia
Polyrizon announces initiation of preclinical studies for Benzodiazepines - TipRanks
Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment - The Manila Times
Polyrizon begins preclinical studies for seizure treatment By Investing.com - Investing.com Nigeria
Why Coinbase Global Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Polyrizon, Pheton, AirSculpt: Top 3 Healthcare Stocks With Soaring Weekly Retail Interest - MSN
Promising Small Cap Stocks To Follow NowMay 4th - MarketBeat
Best Small Cap Stocks To ConsiderMay 3rd - MarketBeat
Polyrizon Ltd. Announces 1-for-10 Reverse Share Split Effective May 5, 2025 - TipRanks
US Stocks Likely To Open Lower After S&P 500's 9-Day Streak: 'Any De-Escalation In Trade Tensions Should Be Positive,' Says Expert - Benzinga
Why Faraday Future Intelligent Electric Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket - Benzinga
Polyrizon, Pheton, AirSculpt: Top 3 Healthcare Stocks With Soaring Weekly Retail Interest By Stocktwits - Investing.com India
Upcoming Stock Splits This Week (May 5 to May 9) – Stay Invested - TipRanks
PLRZPolyrizon Ltd Latest Stock News & Market Updates - Stock Titan
Promising Biotech Stocks To Watch Today – May 2nd - Defense World
United States shares higher at close of trade; Dow Jones Industrial Average up 1.39% - Investing.com India
Nasdaq Surges Over 300 Points; Apple Shares Fall After Q2 Results - Benzinga
PLRZ Stock: Exploring Polyrizon Ltd’s Growth - investchronicle.com
Polyrizon (PLRZ) Stock Skyrocketed Over 240% Today: What's Going On? - Benzinga
PLRZ’s price-to-cash ratio: How it affects the stock’s valuation. - uspostnews.com
Polyrizon Ltd Stock (PLRZ) Financials Data
There is no financial data for Polyrizon Ltd (PLRZ). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):